Highest-materiality recent filing
Q1 revenue $432K (200% YoY) driven by medical device segment (+73%) and new Flyte aviation platform.
Catheter Precision closes $3.47M Series C-2 preferred; issues $11M Series D for Flyte acquisition
3,470 shares of Series C-2 Preferred at $1,000 stated value sold for gross proceeds of $3,470,000.
Catheter Precision shareholders approve reverse split (1:2-1:100) and preferred share issuances
All six proposals passed at April 15 special meeting; 49.5% of outstanding shares voted.
Catheter Precision FY2025 rev +95% to $819K; net loss $17.2M; acquires Flyte aviation platform
Revenue $819K in FY2025, up 95% from $420K in FY2024; gross margin improved to 92.3% from 90.0%.
Catheter Precision acquires 80% of Fly Flyte and Ponderosa Air for $11.6M; raises up to $39M in PIPE
Acquisition of 80.02% of Fly Flyte, Inc. and 100% of Ponderosa Air from Creatd for $11.55M in cash and Series D preferred stock.
CEO David Jenkins exchanged royalty rights for ~9,490 shares of Series J Preferred Stock convertible into 6,083,005 common shares at $1.56, subject to stockholder approval.
Catheter Precision raises $2.18M in private placement, acquires 19.98% stake in FLYTE for $5.25M
Initial closing of private placement yields $2.18M; additional closings could raise up to ~$44.6M total.
Catheter Precision effects 1-for-19 reverse stock split effective August 15, 2025
Reverse stock split at ratio of 1-for-19; effective 12:01 a.m. ET on August 15, 2025.
Catheter Precision Q2 revenue up 128% YoY to $212K; net loss $5.4M with $3.2M non-cash
Revenue $212K for Q2 2025 vs $93K in Q2 2024, 128% increase; sequential growth 48%.
Catheter Precision announces 1-for-19 reverse stock split effective August 15, 2025
Reverse split ratio of 1-for-19 approved by board after shareholder authorization at July 25 annual meeting.
Catheter Precision sees record Q2 LockeT sales; Italy distributor secured
Q2 2025 LockeT sales on track to be highest to date, outpacing Q2 2024 by more than $84,000.
Catheter Precision Q1 revenue up 74% to $143K, net loss $4.0M; cash $450K
Revenue $143K vs $82K YoY (+74%); net loss $4.0M including $1.2M non-cash charges.
Mr. David Jenkins, the Company’s Executive Chairman of the Board and Chief Executive Officer, will fill the role of Chief Commercial Officer until a replacement is engaged.
On June 2, 2025, Catheter Precision, Inc. (the “Company”) discontinued the employment of Marie-Claude Jacques, the Company’s Chief Commercial Officer.
Max materiality 0.85 · Median 0.60 · Most common event other_material